What is CRISPR Therapeutics AG 1-Year Sharpe Ratio?
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-07-06), CRISPR Therapeutics AG's 1-Year Sharpe Ratio is Not available.
Competitive Comparison of CRISPR Therapeutics AG's 1-Year Sharpe Ratio
For the Biotechnology subindustry, CRISPR Therapeutics AG's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG's 1-Year Sharpe Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's 1-Year Sharpe Ratio falls into.
CRISPR Therapeutics AG 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
CRISPR Therapeutics AG (NAS:CRSP) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
CRISPR Therapeutics AG 1-Year Sharpe Ratio Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your